Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-Based Therapy for Intermediate-Risk Hodgkin Lymphoma (AHOD0031)
NCT00025259Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Sep 2002
- Primary completion
- Aug 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of Cisplatin micelle injection (HA132), cytarabine in Hodgkin lymphoma (HL), sponsored by Children's Oncology Group. Started Sep 2002; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)cytarabine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00025259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025259.